Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
Published Online: 2023-01-07
Journal: OncogeneLoading...
Authors: A. Bertucci•A. Gonçalves•B. Renouf•C. Bailleux•C. Blonz•D. Bello Roufai•D. Loirat•E. Renaud•F. C. Bidard•F. Lerebours•H. Simon•I. Desmoulins•J. Gligorov•J. Grenier•J. Y. Pierga•L. Robert•M-A Benderra•M. Bertho•M. Saghatchian•P. Cottu•S. Akla•S. Delaloge•T. De La Motte Rouge•Z. Tharin
